Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70367 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yumi Yamamoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Huntington Disease, Huntingtin Protein, Oligonucleotides, Antisense, Oligonucleotides. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Medical Research Council UK, MR/M008592/1, CHDI Foundation, Inc.
Abstract (Originalsprache)
Aim
Intrathecally administered antisense oligonucleotide tominersen aims to slow Huntington's disease progression by lowering mutant huntingtin (mHTT) protein levels. This study used non‐linear mixed effects population pharmacokinetic and pharmacodynamic (PKPD) modelling to characterize the relationship between tominersen concentration in cerebrospinal fluid (CSF) and CSF mHTT reduction. Additionally, the relationship between tominersen CSF exposure and changes in other CSF biomarkers was investigated to understand tominersen's pharmacodynamic profile. Finally, PKPD model simulations were conducted to inform the dose selection in the GENERATION HD2 study.
Methods
Data from four clinical studies, including 915 participants receiving placebo or tominersen doses (30–120 mg) every 4, 8 or 16 weeks for up to 25 months, were used to develop the PKPD model. The model was utilized to predict tominersen CSF exposure metrics for individual patients in the GENERATION HD1 study for the exposure–response (ER) analysis and to simulate the PK and PD profiles for lower doses.
Results
An indirect‐response model described the relationship between tominersen CSF concentration and mHTT reduction, estimating a half‐maximal inhibitory concentration (IC 50 ) of 4.18 ng/mL. The ER analysis revealed that the highest exposure quartile showed a 54% mHTT reduction at steady state and transient elevations in biomarkers of neuroinjury and inflammation. In contrast, the lowest exposure quartile had a 24% mHTT reduction and a favourable biomarker profile.
Conclusions
The PKPD model quantitatively confirms the relationship between tominersen exposure and CSF mHTT lowering. The ER analysis suggests that lower tominersen exposure levels may offer a better benefit–risk profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Pharmetheus AB, Uppsala, Sweden.
- Roche Products Limited, Welwyn Garden City, UK.
- Georgetown University School of Medicine, Washington, DC, USA.
- University of British Columbia, Vancouver, British Columbia, Canada.
- Ulm University, Ulm, Germany.
ORCID-Profile: Yumi Yamamoto
Förderung
- Medical Research Council UK
- MR/M008592/1
- CHDI Foundation, Inc
- CHDI Foundation
Zitieren
APA
Yamamoto, Y., Silber Baumann, H. E., Björnsson, M., Grimsey, P., Hawellek, D. J., Anderson, K., Leavitt, B. R., Landwehrmeyer, B. G., Tabrizi, S., McColgan, P., Wild, E. J., & Sanwald Ducray, P. (2025). Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70367
Vancouver
Yamamoto Y, Silber Baumann HE, Björnsson M, Grimsey P, Hawellek DJ, Anderson K, et al. Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70367
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Yumi and Silber Baumann, Hanna E and Björnsson, Marcus and Grimsey, Paul and Hawellek, David J and Anderson, Karen and Leavitt, Blair R and Landwehrmeyer, Bernhard G and Tabrizi, Sarah and McColgan, Peter and Wild, Edward J and Sanwald Ducray, Patricia},
title = {Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70367}
}
EUVIMED